Findings

What do systematic reviews say?

84 questions · 84 findings · 4 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 17.9%GRADE not reported 2 · 2.4%Very low 41 · 48.8%Low 23 · 27.4%Moderate 3 · 3.6%High 0 · 0%

Antioxidants vs placebo

Ataxia rating score ICARS; range 0 to 100) · people with Friedreich ataxia

1 finding from 1 review

Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 72 participants
Low

Antioxidants vs placebo

Ejection fraction · people with Friedreich ataxia

1 finding from 1 review

Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Antioxidants vs placebo

End‐diastolic interventricular septal thickness (IVSTd) Measured in mm · people with Friedreich ataxia

1 finding from 1 review

Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 72 participants
Very low

Antioxidants vs placebo

Left ventricular mass · people with Friedreich ataxia

1 finding from 1 review

Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Antioxidants vs placebo

Survival (not measured) · people with Friedreich ataxia

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antioxidants vs placebo

Severe adverse events · people with Friedreich ataxia

Antioxidant showed no clear difference in severe adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
RR 1 [0.07, 15]
2 studies · 72 participants
Low

Gabapentin vs placebo

Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbamazepine vs placebo

Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome

It is very uncertain whether carbamazepine changes rescue analgesic consumption compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings table ‐ Methylprednisolone vs placebo

Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Methylprednisolone vs placebo

Number of participants with pain after 4 weeks · patients with pain in Guillain‐Barré syndrome

Methylprednisolone showed no clear difference in number of participants with pain after 4 weeks compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
RR 0.89 [0.68, 1.16]
1 study · 223 participants
Low

Summary of findings table ‐ Methylprednisolone vs placebo

Number of participants with decreased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome

Methylprednisolone showed no clear difference in number of participants with decreased pain after 4 weeks compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
RR 0.95 [0.63, 1.42]
1 study · 223 participants
Low

Summary of findings table ‐ Methylprednisolone vs placebo

Number of participants with increased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome

Methylprednisolone showed no clear difference in number of participants with increased pain after 4 weeks compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
RR 0.85 [0.52, 1.41]
1 study · 223 participants
Low

Gabapentin vs carbamazepine

Participant‐reported pain relief of 50% or greater · intensive care unit in India

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs carbamazepine

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · intensive care unit in India

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Very low

Gabapentin vs carbamazepine

Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · intensive care unit in India

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Very low

Gabapentin vs carbamazepine

Rescue analgesic consumption · intensive care unit in India

It is very uncertain whether gabapentin changes rescue analgesic consumption compared with carbamazepine (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Very low

Gabapentin vs placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome

It is very uncertain whether gabapentin changes pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 =… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 54 participants
Very low

Gabapentin vs placebo

Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome

It is very uncertain whether gabapentin changes sedation score (numerical rating scale of 1 to 6: 0 = anxious,… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 54 participants
Very low

Gabapentin vs placebo

Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome

It is very uncertain whether gabapentin changes rescue analgesic consumption compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 54 participants
Very low

Gabapentin vs placebo

Nausea · patients with pain in Guillain‐Barré syndrome

It is very uncertain whether gabapentin changes nausea compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.04]
1 study · 18 participants
Very low